Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Base de datos
Tipo del documento
Intervalo de año
1.
Molecules ; 26(19)2021 Sep 30.
Artículo en Inglés | MEDLINE | ID: covidwho-1444276

RESUMEN

Data obtained from several intensive care units around the world have provided substantial evidence of the strong association between impairment of the renal function and in-hospital deaths of critically ill COVID-19 patients, especially those with comorbidities and requiring renal replacement therapy (RRT). Acute kidney injury (AKI) is a common renal disorder of various etiologies characterized by a sudden and sustained decrease of renal function. Studies have shown that 5-46% of COVID-19 patients develop AKI during hospital stay, and the mortality of those patients may reach up to 100% depending on various factors, such as organ failures and RRT requirement. Catechins are natural products that have multiple pharmacological activities, including anti-coronavirus and reno-protective activities against kidney injury induced by nephrotoxic agents, obstructive nephropathies and AKI accompanying metabolic and cardiovascular disorders. Therefore, in this review, we discuss the anti-SARS-CoV-2 and reno-protective effects of catechins from a mechanistic perspective. We believe that catechins may serve as promising therapeutics in COVID-19-associated AKI due to their well-recognized anti-SARS-CoV-2, and antioxidant and anti-inflammatory properties that mediate their reno-protective activities.


Asunto(s)
Lesión Renal Aguda/etiología , Antivirales/farmacología , COVID-19/complicaciones , Catequina/farmacología , Sustancias Protectoras/farmacología , Lesión Renal Aguda/tratamiento farmacológico , Animales , Antivirales/química , Antivirales/uso terapéutico , Catequina/química , Catequina/uso terapéutico , Humanos , Sustancias Protectoras/química , Sustancias Protectoras/uso terapéutico , SARS-CoV-2/efectos de los fármacos , Tratamiento Farmacológico de COVID-19
2.
Molecules ; 25(23)2020 Dec 07.
Artículo en Inglés | MEDLINE | ID: covidwho-966360

RESUMEN

The inflammatory mediator and oxidant agent storm caused by the SARS-CoV-2 infection has been strongly associated with the failure of vital organs observed in critically ill patients with coronavirus disease 2019 (COVID-19) and the death of thousands of infected people around the world. Acute kidney injury (AKI) is a common renal disorder characterized by a sudden and sustained decrease in renal function with a critical influence on poor prognosis and lethal clinical outcomes of various etiologies, including some viral infection diseases. It is known that oxidative stress and inflammation play key roles in the pathogenesis and development of AKI. Quercetin is a natural substance that has multiple pharmacological properties, such as anti-inflammatory action, and is used as a dietary supplement. There is evidence of the anti-coronavirus activities of this compound, including against the target SARS-CoV-2 3CLpro. The ability to inhibit coronavirus and its inflammatory processes is strongly desired in a new drug for the treatment of COVID-19. Therefore, in this review, the dual effect of quercetin is discussed from a mechanistic perspective in relation to AKI kidney injury and its nephroprotective potential to SARS-CoV-2 patients.


Asunto(s)
Lesión Renal Aguda/tratamiento farmacológico , COVID-19/complicaciones , Quercetina/farmacología , Lesión Renal Aguda/etiología , Animales , COVID-19/epidemiología , Humanos , Morbilidad , Sustancias Protectoras/farmacología , Sustancias Protectoras/uso terapéutico , Quercetina/uso terapéutico , Tratamiento Farmacológico de COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA